Ventyx Biosciences Inc
Closed
13.99
Overview
Share price change
24h
Min
13.99
Max
13.99
Income | 4.2M -23M |
|---|---|
Employees | 83 |
EBITDA | 6.6M -23M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | -4.43% downside |
Market Cap | 418M 1B |
|---|---|
Previous open | 13.99 |
Previous close | 13.99 |
Ventyx Biosciences Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Ventyx Biosciences Inc Forecast
Price Target
By TipRanks
-4.43% downside
12 Months Forecast
Average 13.38 USD -4.43%
High 14 USD
Low 9 USD
Based on 8 Wall Street analysts offering 12 month price targets forVentyx Biosciences Inc - Dist in the last 3 months.
Financials
$
About Ventyx Biosciences Inc
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
